Insider Selling: Apogee Therapeutics, Inc. (NASDAQ:APGE) Insider Sells 4,540 Shares of Stock

Apogee Therapeutics, Inc. (NASDAQ:APGE) insider Carl Dambkowski sold 4,540 shares of the company’s stock in a transaction dated Wednesday, December 11th. The stock was sold at an average price of $48.76, for a total transaction of $221,370.40. Following the completion of the sale, the insider now directly owns 258,073 shares of the company’s stock, valued at $12,583,639.48. The trade was a 1.73 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

Carl Dambkowski also recently made the following trade(s):

• On Wednesday, December 4th, Carl Dambkowski sold 6,665 shares of Apogee Therapeutics stock. The stock was sold at an average price of $46.07, for a total value of $307,056.55.
• On Wednesday, November 6th, Carl Dambkowski sold 6,665 shares of Apogee Therapeutics stock. The shares were sold at an average price of $59.12, for a total value of $394,034.80.
• On Wednesday, October 2nd, Carl Dambkowski sold 6,665 shares of Apogee Therapeutics stock. The shares were sold at an average price of $56.26, for a total transaction of $374,972.90.

Apogee Therapeutics Stock Performance

Shares of NASDAQ APGE traded up $0.18 during mid-day trading on Friday, reaching $44.50. The company had a trading volume of 691,879 shares, compared to its average volume of 504,108. The company has a market capitalization of $2.00 billion, a price-to-earnings ratio of -18.39 and a beta of 2.30. The stock has a fifty day moving average of $51.43 and a two-hundred day moving average of $48.28. Apogee Therapeutics, Inc. has a 12-month low of $20.78 and a 12-month high of $72.29.

Institutional Investors Weigh In On Apogee Therapeutics

A number of institutional investors have recently modified their holdings of the stock. Arizona State Retirement System increased its stake in shares of Apogee Therapeutics by 4.5% in the second quarter. Arizona State Retirement System now owns 5,993 shares of the company’s stock worth $236,000 after acquiring an additional 258 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. increased its position in Apogee Therapeutics by 21.2% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,628 shares of the company’s stock worth $94,000 after purchasing an additional 285 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank purchased a new stake in shares of Apogee Therapeutics during the 3rd quarter worth about $71,000. Principal Financial Group Inc. lifted its holdings in shares of Apogee Therapeutics by 26.3% during the 2nd quarter. Principal Financial Group Inc. now owns 6,442 shares of the company’s stock valued at $253,000 after buying an additional 1,340 shares during the last quarter. Finally, Handelsbanken Fonder AB grew its stake in shares of Apogee Therapeutics by 25.7% in the 3rd quarter. Handelsbanken Fonder AB now owns 8,800 shares of the company’s stock valued at $517,000 after buying an additional 1,800 shares in the last quarter. Institutional investors and hedge funds own 79.04% of the company’s stock.

Wall Street Analyst Weigh In

A number of brokerages have recently issued reports on APGE. Canaccord Genuity Group started coverage on Apogee Therapeutics in a research report on Monday, November 25th. They set a “buy” rating and a $89.00 target price on the stock. Guggenheim restated a “buy” rating on shares of Apogee Therapeutics in a report on Thursday. Canaccord Genuity Group began coverage on shares of Apogee Therapeutics in a report on Monday, November 25th. They issued a “buy” rating and a $89.00 target price for the company. Finally, Wedbush boosted their price target on shares of Apogee Therapeutics from $87.00 to $90.00 and gave the company an “outperform” rating in a report on Monday, December 2nd. Eight analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company has a consensus rating of “Buy” and a consensus price target of $83.88.

Apogee Therapeutics Company Profile

Apogee Therapeutics, Inc, through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD.